Korean J Med.
2009 Nov;77(5):559-564.
Molecular targeted therapy of thyroid cancer
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
- Novel molecular-targeted therapies involving various kinds of kinase inhibitors show promising results in the treatment of advanced thyroid carcinoma refractory to conventional treatment such as surgery and radioiodine treatment. Partial response rates around 15~30% and disease stabilization in additional 30~60% are reported in clinical trials using these drugs. In this review, the introduction about many kinase inhibitors in clinical trials nowadays and the results focusing on phase 2 trial will be discussed. With the development of this various kinds of potent kinase inhibitors and encouragement of enrollment to further clinical trials will give hope to the patients with refractory thyroid cancer in the near future.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- New Strategies for Combined Radioiodine Therapy in Refractory Thyroid Cancer
- Diagnostic and Therapeutic Approaches to Radioactive Iodine Refractory Differentiated Thyroid Cancer
- Combinatorial Targeted Therapy in Thyroid Cancer
- Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
- New Targeted Therapy for Non-Small Cell Lung Cancer
